Clinical Trials

JZP712-101 - A Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Recommended Phase 2 Dose (RP2D), and Efficacy of Lurbinectedin Monotherapy in Pediatric Participants With Previously Treated Solid Tumors Followed by Expansion to Assess Efficacy and Safety in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma.

Link : https://www.clinicaltrials.gov/ct2/show/NCT05734066
Status : span class="RECRUITINGgreen">RECRUITING
Population : 2 Years to 30 Years with Relapsed/Refractory Ewing Sarcoma
Description : Lurbinectedin Monotherapy
PI : D. Morgenstern
Centers Opened : SickKids
Phase : I/II
IIST/Pharma : Pharma